Adlai Nortye LTD. (ANL) — 6-K Filings

6-K Filings (11)

• Adlai Nortye Reports H1 2025 Results & Pipeline Update — Dec 29, 2025 Risk: medium
  Adlai Nortye Ltd. reported its unaudited first half 2025 financial results and provided an update on its operational progress. The company highlighted its pipel
• Adlai Nortye Ltd. Redomiciles to Singapore, Renames to Adlai Nortye Group Ltd. — Dec 3, 2025 Risk: low
  Adlai Nortye Ltd. held its 2025 Extraordinary General Meeting of Shareholders on December 1, 2025, where all proposed resolutions were passed. Shareholders appr
• Adlai Nortye Ltd. Calls Extraordinary General Meeting — Oct 22, 2025 Risk: medium
  Adlai Nortye Ltd. filed a Form 6-K on October 22, 2025, to report an upcoming Extraordinary General Meeting of Shareholders. The filing includes the notice of t
• Adlai Nortye Ltd. Adopts 2025 Share Incentive Plan — Jul 9, 2025 Risk: low
  Adlai Nortye Ltd. announced the adoption of its 2025 Share Incentive Plan on July 1, 2025. This plan allows the company to grant awards such as options, restric
• Adlai Nortye's Phase III HNSCC Trial Misses Primary Endpoint — May 30, 2025 Risk: high
  Adlai Nortye Ltd. announced on May 30, 2025, the topline results of its Phase III BURAN trial for buparlisib (AN2025) in combination with paclitaxel. The trial
• Adlai Nortye CFO Resigns, Stays On As Consultant — Dec 31, 2024 Risk: medium
  Adlai Nortye Ltd. announced that its Chief Financial Officer, Ms. Vicky Wei Zhang, has resigned effective December 31, 2024, due to personal career development.
• Adlai Nortye Reports H1 2024 Results & New Director — Aug 8, 2024 Risk: medium
  Adlai Nortye Ltd. filed a Form 6-K on August 8, 2024, reporting its unaudited financial results for the first half of 2024. The filing also highlighted recent o
• Adlai Nortye CEO & CMO Resigns, Remains Director — Jul 3, 2024 Risk: medium
  Adlai Nortye Ltd. announced on July 2, 2024, that Dr. Lars E. Birgerson has resigned as President, Chief Medical Officer, and CEO of its US subsidiary, effectiv
• Adlai Nortye Auditor Mazars Merges with FORVIS — Jun 27, 2024 Risk: low
  Adlai Nortye Ltd. announced a change in its independent registered public accounting firm. Mazars USA LLP, the company's auditor, merged with FORVIS, LLP on Jun
• Adlai Nortye to Present AN0025 Data at ASCO 2024 — May 24, 2024 Risk: medium
  Adlai Nortye Ltd. announced on May 24, 2024, that it will present encouraging data on the combination of its drug AN0025 with definitive chemoradiotherapy (dCRT
• Adlai Nortye Appoints Dr. Archie Tse as Head of R&D — Apr 2, 2024 Risk: medium
  Adlai Nortye Ltd. announced on April 2, 2024, the appointment of Dr. Archie Tse as the Head of Research & Development. Dr. Tse brings extensive experience in on

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX